Core Viewpoint - The company, Haizheng Shengcai, has confirmed its commitment to regularly disclose the number of shareholders as required, and investors are advised to pay attention to the relevant content in periodic reports [2] Group 1 - The company responded to investor inquiries on November 19 regarding shareholder information [2] - The company emphasizes adherence to disclosure requirements [2]

Summary of Key Points Core Viewpoint - The stock of Haizheng Biomaterials (688203) has shown a slight increase, with a closing price of 13.46 yuan as of November 14, 2025, reflecting a 1.51% rise from the previous week [1]. Stock Performance - The highest price during the week was 13.93 yuan on November 13, while the lowest was 13.19 yuan on November 12 [1]. - The current total market capitalization of Haizheng Biomaterials is 2.728 billion yuan, ranking 64th out of 71 in the plastics sector and 4818th out of 5165 in the A-share market [1]. Shareholder Changes - China Petroleum & Chemical Corporation Capital Co., Ltd. reduced its holdings by 1% (2,026,700 shares) between October 28 and November 11, 2025, due to funding needs [1][3]. - The share price during the reduction ranged from 12.84 to 13.49 yuan per share, with a total reduction amounting to approximately 26.73 million yuan [1][3]. - After the reduction, China Petroleum Capital holds 10,788,194 shares, representing 5.32% of the total share capital [1][3].

Group 1 - The stock price of Zhejiang Haizheng Biomaterials Co., Ltd. (688203) closed at 13.5 yuan on November 13, 2025, with an increase of 1.28% and a turnover rate of 2.76% [1] - The trading volume on that day was 34,300 shares, with a total transaction amount of 46.89 million yuan [1] - The net inflow of main funds was 1.9858 million yuan, accounting for 4.23% of the total transaction amount, while retail investors had a net outflow of 5.0205 million yuan, representing 10.71% of the total transaction amount [1][3] Group 2 - China Petroleum & Chemical Corporation Capital Co., Ltd., a major shareholder with over 5% stake, reduced its holdings in Haizheng Biomaterials by 2,026,700 shares, which is 1% of the total share capital, between October 28 and November 11, 2025 [2] - The reduction price range was between 12.84 and 13.49 yuan per share, totaling approximately 26.73 million yuan [2] - After the reduction, China Petroleum Capital holds 10,788,194 shares, representing 5.32% of the total share capital [2][3]

Core Viewpoint - The recent share reduction by a major shareholder, Sinopec Capital, indicates a strategic move to meet operational funding needs, which may impact investor sentiment and stock performance in the short term [1]. Group 1: Stock Performance - As of November 12, 2025, the stock of Zhejiang Haizheng Biomaterials Co., Ltd. (688203) closed at 13.33 yuan, down 0.67% from the previous trading day [1]. - The stock opened at 13.45 yuan, reached a high of 13.50 yuan, and a low of 13.19 yuan, with a trading volume of 28.59 million yuan and a turnover rate of 1.73% [1]. Group 2: Shareholder Actions - Sinopec Capital, holding over 5% of shares, reduced its stake by 2,026,700 shares, representing 1% of the total share capital, between October 28 and November 11, 2025 [1]. - The reduction occurred at a price range of 12.84 to 13.49 yuan per share, totaling approximately 26.73 million yuan [1]. - Post-reduction, Sinopec Capital holds 10,788,194 shares, accounting for 5.32% of the total share capital, consistent with the previously disclosed reduction plan [1].

Core Points - The announcement from Zhejiang Haizheng Biomaterials Co., Ltd. indicates that its major shareholder, Sinopec Capital, has reduced its stake in the company [2] - Sinopec Capital held 12,814,894 shares, representing 6.32% of the total share capital before the reduction [2] - As of November 11, 2025, Sinopec Capital has sold 2,026,700 shares through centralized bidding, which is 1% of the total share capital [2] - After the completion of the reduction plan, Sinopec Capital now holds 10,788,194 shares, accounting for 5.32% of the total share capital [2]

Group 1 - The core point of the article is that Sinopec Capital has completed a share reduction plan for Haizheng Biomaterials, reducing its stake to 5.32% of the total shares outstanding [1] - As of November 11, 2025, Sinopec Capital has reduced its holdings by 2,026,700 shares, which represents 1% of the total share capital of Haizheng Biomaterials [1] - Following the reduction, Sinopec Capital now holds 10,788,194 shares in Haizheng Biomaterials [1] Group 2 - Haizheng Biomaterials reported that its revenue composition for the year 2024 is heavily weighted towards the fiber manufacturing industry, accounting for 98.77% of total revenue [1] - The company's other business segments contribute only 1.23% to its overall revenue [1] - As of the latest report, Haizheng Biomaterials has a market capitalization of 2.7 billion yuan [2]

证券代码：688203 证券简称：海正生材 公告编号：2025-56 浙江海正生物材料股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 浙江海正生物材料股份有限公司（以下简称"公司"或"海正生材"）持股 5%以上股东中国石化集团资本有限公司（以下简称"中石化资本"）持有公司股 份 12,814,894 股，占公司总股本的 6.32%。上述股份为公司首次公开发行前取 得的股份，并已于 2024 年 2 月 19 日起上市流通。 减持计划的实施结果情况 | 股东名称 | 中国石化集团资本有限公司 | | | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 √否 | | | 直接持股 5%以上股东 | √是 □否 | | | 董事、监事和高级管理人员 | □是 √否 | | | 其他：/ | | | 持股数量 | 12,814,894股 | | | 持股比例 | 6.32% | | | 当前持股股份来 ...

Group 1 - The core point of the article is that the company, Hai Zheng Sheng Cai (688203.SH), has completed a share reduction plan initiated by its shareholder, Sinopec Capital [1] - As of November 11, 2025, Sinopec Capital has reduced its holdings by a total of 2.0267 million shares, which represents 1% of the company's total share capital [1]

Core Viewpoint - Sinopec Capital, a shareholder holding more than 5% of the shares, has reduced its stake in Haizheng Biomaterials due to funding needs for business development, completing the reduction plan as of November 11 [1] Group 1: Shareholder Reduction - Sinopec Capital originally held 12,814,894 shares, accounting for 6.32% of the total share capital [1] - The reduction plan was disclosed on September 26, 2025, allowing for a maximum reduction of 2,026,700 shares, which is up to 1% of the total share capital [1] - As of November 11, Sinopec Capital has completed the reduction, selling 2,026,700 shares for a total amount of 26.73 million yuan, reducing its holding to 10,788,194 shares, which is 5.32% of the total share capital [1]

Group 1 - The company Zhejiang Haizheng Biomaterials Co., Ltd. has approved a share repurchase plan to buy back its A-shares using its own funds, with a maximum price of RMB 12.00 per share and a total repurchase amount between RMB 20 million and RMB 30 million [2] - The repurchase period is set for a maximum of 12 months from the date of board approval, which is August 28, 2024 [2] - As of October 31, 2025, the company has repurchased a total of 1,900,000 shares, accounting for 0.937% of the total share capital, with a total expenditure of approximately RMB 20.49 million [2][5] Group 2 - The company adjusted the source of repurchase funds from "own funds" to include "own funds and special loans for stock repurchase" as of March 11, 2025 [2] - The maximum repurchase price was later increased to RMB 17.00 per share, and the repurchase period was extended by 6 months to February 27, 2026 [2] - The highest and lowest prices for the repurchased shares were RMB 15.98 and RMB 7.76 per share, respectively [2] Group 3 - On November 3, 2025, the company received a notice from its shareholder, Sinopec Group Capital Co., Ltd., regarding a reduction in shareholding [6] - Sinopec Group Capital reduced its holdings by 783,484 shares, bringing its total shares down to 12,031,410, which is 5.94% of the total share capital [6][7] - This reduction is part of a previously disclosed share reduction plan and will not affect the company's controlling shareholder or its governance structure [7][8]